RHJA
ACAD icon

Rice Hall James & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Rice Hall James & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Buy
618,887
+1,398
+0.2% +$30.8K 0.76% 43
2026
Q1 		$13.7M Buy
617,489
+13,749
+2% +$329K 0.77% 42
2025
Q4 		$16.1M Sell
603,740
-11,197
-2% -$268K 0.89% 36
2025
Q3 		$13.1M Sell
614,937
-54,869
-8% -$1.3M 0.72% 45
2025
Q2 		$14.4M Sell
669,806
-2,417
-0.4% -$44.9K 0.78% 38
2025
Q1 		$11.2M Sell
672,223
-9,314
-1% -$169K 0.66% 43
2024
Q4 		$12.5M Sell
681,537
-35,609
-5% -$575K 0.69% 44
2024
Q3 		$11M Sell
717,146
-25,789
-3% -$430K 0.6% 47
2024
Q2 		$12.1M Buy
742,935
+78,379
+12% +$1.26M 0.72% 40
2024
Q1 		$12.3M Sell
664,556
-28,296
-4% -$701K 0.7% 40
2023
Q4 		$21.7M Sell
692,852
-3,213
-0.5% -$76.7K 1.26% 19
2023
Q3 		$14.5M Sell
696,065
-190,388
-21% -$5.17M 0.92% 33
2023
Q2 		$21.2M Sell
886,453
-673
-0.1% -$15K 1.2% 19
2023
Q1 		$16.7M Sell
887,126
-70,562
-7% -$1.34M 0.95% 28
2022
Q4 		$15.2M Buy
957,688
+433,818
+83% +$6.78M 0.87% 35
2022
Q3 		$8.57M Sell
523,870
-19,658
-4% -$318K 0.5% 53
2022
Q2 		$7.66M Buy
543,528
+80,224
+17% +$1.5M 0.37% 65
2022
Q1 		$11.2M Buy
463,304
+2,253
+0.5% +$54.5K 0.45% 63
2021
Q4 		$10.8M Sell
461,051
-35,706
-7% -$718K 0.38% 63
2021
Q3 		$8.25M Sell
496,757
-16,125
-3% -$311K 0.3% 72
2021
Q2 		$12.5M Sell
512,882
-61,054
-11% -$1.38M 0.44% 61
2021
Q1 		$14.8M Buy
573,936
+299,777
+109% +$13.2M 0.48% 58
2020
Q4 		$14.7M Sell
274,159
-820
-0.3% -$40.7K 0.52% 55
2020
Q3 		$11.3M Buy
274,979
+83,021
+43% +$3.59M 0.46% 58
2020
Q2 		$9.3M Sell
191,958
-4,137
-2% -$199K 0.4% 67
2020
Q1 		$8.29M Buy
+196,095
New +$8.08M 0.46% 64

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rice Hall James & Associates's ACAD Position: Q2 2026 in Review

Rice Hall James & Associates increased its Acadia Pharmaceuticals (ACAD) stake by 0.23% in Q2 2026, buying an estimated $30.8K and bringing the position to 618,887 shares worth $15.7M. The position accounts for 0.76% of the portfolio, ranked #43.

Rice Hall James & Associates first reported a position in ACAD in Q1 2020 and has held it in 26 quarters since. The position peaked at $21.7M in Q4 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Rice Hall James & Associates held 618,887 shares of Acadia Pharmaceuticals worth $15.7M as of Q2 2026.
  • Rice Hall James & Associates bought 1,398 Acadia Pharmaceuticals shares in Q2 2026, an estimated $30.8K.
  • Acadia Pharmaceuticals made up 0.76% of Rice Hall James & Associates's portfolio in Q2 2026, its #43 holding.
  • Rice Hall James & Associates first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Rice Hall James & Associates's Acadia Pharmaceuticals position peaked at $21.7M in Q4 2023.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.